Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFκB and E2F in a rabbit model

Cardiovascular Research

Volumn 79, Issue 4, 2008, Pages 706-714

  Miyake, Takashi ^a   Aoki, Motokuni ^b   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

Author keywords

Cardiovascular surgery; E2F; Gene therapy; NF B; Restenosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OLIGODEOXYNUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSCRIPTION FACTOR E2F; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERPLASIA; INTIMA; NONHUMAN; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANASTOMOSIS, SURGICAL; ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; E2F TRANSCRIPTION FACTORS; ENDOTHELIAL CELLS; FEASIBILITY STUDIES; GENE THERAPY; HYPERCHOLESTEROLEMIA; HYPERPLASIA; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; OLIGONUCLEOTIDES; PLATELET-DERIVED GROWTH FACTOR; RABBITS; TRANSFECTION; VASCULAR PATENCY;

EID: 52449108695     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn139     Document Type: Article

References (29)

1. Clowes AW, Gown AM, Hanson SR, Reidy MA. Mechanisms of arterial graft failure, 1: role of cellular proliferation in early healing of PTFE prostheses. Am J Pathol 1985;118:43-54.
2. Casscells W. Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation 1992;86:723-729.
3. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-5859.
4. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001;121:714-722.
5. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005;294:2446-2454.
6. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006;43:742-751.
7. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.
8. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995;270:933-943.
9. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999;19:2690-2698.
10. Ballas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995;96:2521-2527.
11. Miyake T, Aoki M, Shiraya S, Tanemoto K, Ogihara T, Kaneda Y et al. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. J Mol Cell Cardiol 2006;41:431-440.
12. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004;118:477-491.
13. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995;92:4502-4506.
14. Mann MJ, Gibbons GH, Tsao PS, von der Leyen HE, Cooke JP, Buitrago R et al. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 1997;99:1295-1301.
15. Lee CH, Jeong TS, Choi YK, Hyun BH, Oh GT, Kim EH et al. Antiatherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits. Biochem Biophys Res Commun 2001;284:681-688.
16. Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S. Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology 1997;198:35-49.
17. Wang Z, Castresana MR, Newman WH. Reactive oxygen and NF-kappaB in VEGF-induced migration of human vascular smooth muscle cells. Biochem Biophys Res Commun 2001;285:669-674.
18. Gomez D, Reich NC. Stimulation of primary human endothelial cell proliferation by IFN. J Immunol 2003;170:5373-5381.
19. Ehsan A, Mann MJ, Dell'Acqua G, Tamura K, Braun-Dullaeus R, Dzau VJ. Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation 2002;105:1686-1692.
20. Munoz-Chapuli R, Quesada AR, Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2004;61:2224- 2243.
21. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89:507-511.
22. Inui H, Kitami Y, Tani M, Kondo T, Inagami T. Differences in signal transduction between PDGFα and β receptors in vascular smooth muscle cells: PDGF-BB is a potent mitogen but PDGF-AA promotes protein synthesis without activation of DNA synthesis. J Biol Chem 1994;269:30546- 30552.
23. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M et al. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 1990;248:1009-1012.
24. Khachigian LM, Resnick N, Gimbrone MA Jr, Collins T. Nuclear factor-kappa B interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J Clin Invest 1995;96:1169-1175.
25. Chen A, Zhang L. The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. J Biol Chem 2003;278:23381-23389.
26. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 1994;81:1254-1269.
27. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-2111.
28. Matsushita H, Morishita R, Nata T, Aoki M, Nakagami H, Taniyama Y et al. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res 2000;86:974- 981.
29. Hamuro M, Polan J, Natarajan M, Mohan S. High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration. Atherosclerosis 2002;162:277-287.